Market Transparency in Medicine Pricing: Pathways to Fair Pricing João L. Carapinha Commentary 09 May 2024 Pages: 611 - 614
Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective Bradley M. SugdenSabine E. GrimmWillem J. A. Witlox Commentary Open access 07 May 2024 Pages: 615 - 618
Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review Tobias Sydendal GrandShijie RenPraveen Thokala Review Article Open access 14 April 2024 Pages: 619 - 631
Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review Clazinus VeijerMarinus H. van HulstAntoinette D.I. van Asselt Systematic Review Open access 10 May 2024 Pages: 633 - 647
Childhood Transitions Between Weight Status Categories: Evidence from the UK Millennium Cohort Study Olu OnyimaduNerys M. AstburyMara Violato Original Research Article Open access 03 April 2024 Pages: 649 - 661
Developing a Program Costs Checklist of Digital Health Interventions: A Scoping Review and Empirical Case Study Zareen Abbas KhanKristian KidholmVidar Halsteinli Original Research Article Open access 26 March 2024 Pages: 663 - 678
Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective? Anna KensethDominika KantorovaJørn Evert Jacobsen Original Research Article 07 April 2024 Pages: 679 - 691
Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States William L. HerringMeghan E. GallagherBiree Andemariam Original Research Article Open access 29 April 2024 Pages: 693 - 714